The metabolic mechanisms of breast cancer metastasis
L Wang, S Zhang, X Wang - Frontiers in Oncology, 2021 - frontiersin.org
Breast cancer is one of the most common malignancy among women worldwide. Metastasis
is mainly responsible for treatment failure and is the cause of most breast cancer deaths …
is mainly responsible for treatment failure and is the cause of most breast cancer deaths …
Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors
The frequent activation of the PI3K/AKT/mTOR pathway in cancer, and its crucial role in cell
growth and survival, has made it a much desired target for pharmacologic intervention …
growth and survival, has made it a much desired target for pharmacologic intervention …
Distinct longevity mechanisms across and within species and their association with aging
Lifespan varies within and across species, but the general principles of its control remain
unclear. Here, we conducted multi-tissue RNA-seq analyses across 41 mammalian species …
unclear. Here, we conducted multi-tissue RNA-seq analyses across 41 mammalian species …
[HTML][HTML] Identification and application of gene expression signatures associated with lifespan extension
A Tyshkovskiy, P Bozaykut, AA Borodinova… - Cell metabolism, 2019 - cell.com
Several pharmacological, dietary, and genetic interventions that increase mammalian
lifespan are known, but general principles of lifespan extension remain unclear. Here, we …
lifespan are known, but general principles of lifespan extension remain unclear. Here, we …
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
A Akinleye, P Avvaru, M Furqan, Y Song… - Journal of hematology & …, 2013 - Springer
Abstract Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that regulate diverse
cellular processes including proliferation, adhesion, survival, and motility. Dysregulated …
cellular processes including proliferation, adhesion, survival, and motility. Dysregulated …
mTOR pathway in colorectal cancer: an update
MG Francipane, E Lagasse - Oncotarget, 2013 - pmc.ncbi.nlm.nih.gov
The mammalian target of rapamycin (mTOR) has emerged as a potential target for drug
development, particularly due to the fact that it plays such a crucial role in cancer biology. In …
development, particularly due to the fact that it plays such a crucial role in cancer biology. In …
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes
Abstract The PI3K-Akt pathway is a vital regulator of cell proliferation and survival.
Alterations in the PIK3CA gene that lead to enhanced PI3K kinase activity have been …
Alterations in the PIK3CA gene that lead to enhanced PI3K kinase activity have been …
Targeting LKB1 signaling in cancer
SE Korsse, MP Peppelenbosch… - Biochimica et Biophysica …, 2013 - Elsevier
The serine/threonine kinase LKB1 is a master kinase involved in cellular responses such as
energy metabolism, cell polarity and cell growth. LKB1 regulates these crucial cellular …
energy metabolism, cell polarity and cell growth. LKB1 regulates these crucial cellular …
PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma
BL Lampson, JR Brown - Expert opinion on investigational drugs, 2017 - Taylor & Francis
Introduction: The efficacy of the prototypical phosphatidylinositol-3-kinase (PI3K) inhibitor
idelalisib for the treatment of chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin …
idelalisib for the treatment of chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin …
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
I Brana, LL Siu - BMC medicine, 2012 - Springer
Abstract The phosphatidylinositol 3-kinase (PI3K) pathway is commonly deregulated in
cancer. In recent years, the results of the first phase I clinical trials with PI3K inhibitors have …
cancer. In recent years, the results of the first phase I clinical trials with PI3K inhibitors have …